Neurocrine Biosciences | NBIX - Acreedores Comerciales





Acreedores Comerciales Cambio Fecha
AbbVie USD 3.59B 28.65B 2025-12
Acadia Pharmaceuticals USD 44.57M 32.32M 2026-06
Agios Pharmaceuticals USD 16.34M 2.6M 2026-06
ALKERMES USD 142.86M 40.5M 2026-06
Alnylam Pharmaceuticals USD 108.02M 18.61M 2026-06
Amgen USD 2.86B 16.65B 2026-06
Biogen USD 403.9M 45.4M 2026-06
BioMarin Pharmaceutical USD 913.67M 120.52M 2026-06
Cytokinetics USD 20.51M 4.2M 2026-06
Enanta Pharmaceuticals USD 1.88M 63K 2025-12
Exelixis USD 39.06M 14.91M 2026-06
Gilead Sciences USD 645M 70M 2026-03
Halozyme Therapeutics USD 23.61M 9.51M 2026-06
Incyte USD 1.39B 1.16B 2026-06
Ionis Pharmaceuticals USD 47.7M 21.67M 2026-06
Nektar Therapeutics USD 10.03M 744K 2026-03
Neurocrine Biosciences USD 691.3M 145.8M 2026-03
Pfizer USD 4.58B 75M 2026-06
Prothena USD 1.94M 2.36M 2026-06
Regeneron Pharmaceuticals USD 1.16B 132.2M 2026-06
Repligen USD 33.23M 1.42M 2026-06
Rigel Pharmaceuticals USD 3.85M 3.44M 2025-09
Sarepta Therapeutics USD 50.98M 19.39M 2026-06
Teva Pharmaceutical Industries USD 2.72B 125M 2026-06
Ultragenyx Pharmaceutical USD 39M 3M 2026-06
Vertex Pharmaceuticals USD 3.61B 135M 2026-06